Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Finished Goods (2020 - 2025)

IceCure Medical (ICCM) has disclosed Finished Goods for 5 consecutive years, with $349000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Finished Goods fell 38.56% to $349000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $349000.0, a 38.56% decrease, with the full-year FY2024 number at $349000.0, down 38.56% from a year prior.
  • Finished Goods was $349000.0 for Q4 2024 at IceCure Medical, down from $568000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $935000.0 in Q4 2022 to a low of $349000.0 in Q4 2024.
  • A 5-year average of $599600.0 and a median of $568000.0 in 2023 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: soared 125.57% in 2021, then tumbled 39.25% in 2023.
  • IceCure Medical's Finished Goods stood at $352000.0 in 2020, then skyrocketed by 125.57% to $794000.0 in 2021, then increased by 17.76% to $935000.0 in 2022, then tumbled by 39.25% to $568000.0 in 2023, then plummeted by 38.56% to $349000.0 in 2024.
  • Per Business Quant, the three most recent readings for ICCM's Finished Goods are $349000.0 (Q4 2024), $568000.0 (Q4 2023), and $935000.0 (Q4 2022).